Drug Profile
Research programme: capillary stem cells - Asahikawa Medical University/Asubio Pharma
Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Asahikawa Medical University; Asubio Pharma
- Developer Asubio Pharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 May 2020 No recent reports of development identified for research development in Cardiovascular-disorders in Japan (Parenteral)
- 05 Apr 2016 Asahikawa Medical University and Daiichi Sankyo Company agree on a joint research collaboration to develop Capillary stem cells
- 05 Apr 2016 Early research in Cardiovascular disorders in Japan (Parenteral)